Literature DB >> 26105812

Effect of single point mutations in a form of systemic amyloidosis.

Manikanthan Bhavaraju1, Ulrich H E Hansmann1.   

Abstract

Amyloid deposits of light-chain proteins are associated with the most common form of systemic amyloidosis. We have studied the effects of single point mutations on amyloid formation of these proteins using explicit solvent model molecular dynamics simulations. For this purpose, we compare the stability of the wild-type immunoglobulin light-chain protein REI in its native and amyloid forms with that of four mutants: R61N, G68D, D82I, and A84T. We argue that the experimentally observed differences in the propensity for amyloid formation result from two effects. First, the mutant dimers have a lower stability than the wild-type dimer due to increase exposure of certain hydrophobic residues. The second effect is a shift in equilibrium between monomers with amyloid-like structure and such with native structures. Hence, when developing drugs against light-chain associated systemic amyloidosis, one should look for components that either stabilize the dimer by binding to the dimer interface or reduce for the monomers the probability of the amyloid form.
© 2015 The Protein Society.

Entities:  

Keywords:  aggregation; light-chain proteins; molecular dynamics; systemic amyloidosis

Mesh:

Substances:

Year:  2015        PMID: 26105812      PMCID: PMC4570539          DOI: 10.1002/pro.2730

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  48 in total

1.  The molecular structure of a dimer composed of the variable portions of the Bence-Jones protein REI refined at 2.0-A resolution.

Authors:  O Epp; E E Lattman; M Schiffer; R Huber; W Palm
Journal:  Biochemistry       Date:  1975-11-04       Impact factor: 3.162

2.  Peptide chain dynamics in light and heavy water: zooming in on internal friction.

Authors:  Julius C F Schulz; Lennart Schmidt; Robert B Best; Joachim Dzubiella; Roland R Netz
Journal:  J Am Chem Soc       Date:  2012-03-27       Impact factor: 15.419

3.  Molecular structure of the amyloid-forming protein kappa I Bre.

Authors:  L K Steinrauf; M Y Chiang; D Shiuan
Journal:  J Biochem       Date:  1999-02       Impact factor: 3.387

4.  Fragments of the constant region of immunoglobulin light chains are constituents of AL-amyloid proteins.

Authors:  K E Olsen; K Sletten; P Westermark
Journal:  Biochem Biophys Res Commun       Date:  1998-10-20       Impact factor: 3.575

5.  Stability of Iowa mutant and wild type Aβ-peptide aggregates.

Authors:  Erik J Alred; Emily G Scheele; Workalemahu M Berhanu; Ulrich H E Hansmann
Journal:  J Chem Phys       Date:  2014-11-07       Impact factor: 3.488

6.  Assessing the performance of MM/PBSA and MM/GBSA methods. 4. Accuracies of MM/PBSA and MM/GBSA methodologies evaluated by various simulation protocols using PDBbind data set.

Authors:  Huiyong Sun; Youyong Li; Sheng Tian; Lei Xu; Tingjun Hou
Journal:  Phys Chem Chem Phys       Date:  2014-08-21       Impact factor: 3.676

7.  Primary systemic amyloidosis: clinical and laboratory features in 474 cases.

Authors:  R A Kyle; M A Gertz
Journal:  Semin Hematol       Date:  1995-01       Impact factor: 3.851

Review 8.  Huntington's disease: from molecular pathogenesis to clinical treatment.

Authors:  Christopher A Ross; Sarah J Tabrizi
Journal:  Lancet Neurol       Date:  2011-01       Impact factor: 44.182

9.  In vivo demonstration that alpha-synuclein oligomers are toxic.

Authors:  Beate Winner; Roberto Jappelli; Samir K Maji; Paula A Desplats; Leah Boyer; Stefan Aigner; Claudia Hetzer; Thomas Loher; Marçal Vilar; Silvia Campioni; Christos Tzitzilonis; Alice Soragni; Sebastian Jessberger; Helena Mira; Antonella Consiglio; Emiley Pham; Eliezer Masliah; Fred H Gage; Roland Riek
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-15       Impact factor: 11.205

10.  X-ray crystallography reveals stringent conservation of protein fold after removal of the only disulfide bridge from a stabilized immunoglobulin variable domain.

Authors:  I Usón; M T Bes; G M Sheldrick; T R Schneider; T Hartsch; H J Fritz
Journal:  Fold Des       Date:  1997
View more
  3 in total

1.  Phase 2 trial of daily, oral epigallocatechin gallate in patients with light-chain amyloidosis.

Authors:  Sohsuke Meshitsuka; Sumito Shingaki; Masatoshi Hotta; Miku Goto; Makoto Kobayashi; Yuuichi Ukawa; Yuko M Sagesaka; Yasuyo Wada; Masanori Nojima; Kenshi Suzuki
Journal:  Int J Hematol       Date:  2016-11-04       Impact factor: 2.490

2.  Structure and energetic basis of overrepresented λ light chain in systemic light chain amyloidosis patients.

Authors:  Jun Zhao; Baohong Zhang; Jianwei Zhu; Ruth Nussinov; Buyong Ma
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-12-12       Impact factor: 5.187

Review 3.  Recent Developments and Applications of the MMPBSA Method.

Authors:  Changhao Wang; D'Artagnan Greene; Li Xiao; Ruxi Qi; Ray Luo
Journal:  Front Mol Biosci       Date:  2018-01-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.